Clinical trials: ifosfamide
Diffuse Large B-Cell Lymphoma
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
The overall purpose of the study is to determine if MEDI-551, when used in combination with salvage chemotherapy, Ifosfamide-carboplatin-etoposide (ICE) or Dexamethasone-cytarabine (DHAP) in patients with relapsed or refractory…
- Trial name
- NCT01453205
- Testing
- MEDI-551 2 mg/kg, Rituximab, ICE
- Where
- 81 sites in United States, Canada and 9 more
- Volunteers
- 187 people
- Sponsor
- MedImmune LLC
Sarcoma
PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET) scan and computated tomography (CT) scan, may help doctors predict a patient's response to treatment and may help plan the best treatment.
- Trial name
- NCT00346125
- Testing
- pegfilgrastim, doxorubicin hydrochloride, ifosfamide
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lymphoma
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00392990
- Testing
- Regimen A, Regimen B
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- Northwestern University
ALK-negative Anaplastic Large Cell Lymphoma, Peripherial T Cell Lymphoma,Not Otherwise Specified
CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
T cell lymphoma is a heterogenic malignancy with poor outcome. Five-year PFS and OS of the patients recieved classic CHOP regimen(cyclophosphamide,vincristin,doxorubicin and predisone)is less than 30%.High dose intensive…
- Conditions
- ALK-negative Anaplastic Large Cell Lymphoma, Peripherial T Cell Lymphoma,Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma, Enteropathy Associated T Cell Lymphoma
- Trial name
- NCT01746992
- Testing
- Cyclophosphamide 750mg/m2, Vincristine 1.4mg/m2, Doxorubicin 50mg/m2
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Ruijin Hospital
Ewing's Sarcoma (ES)
Protocol for the Treatment of Metastatic Ewing Sarcoma
Study for the treatment of metastatic Ewing sarcoma with high doses chemotherapy, radiotherapy and maintenance therapy.
- Trial name
- EW-2 (NCT02727387)
- Testing
- TEMIRI, ADM, IFO
- Where
- 13 sites in Italy
- Volunteers
- 155 people
- Sponsor
- Italian Sarcoma Group
Leukemia
Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002531
- Testing
- asparaginase, cyclophosphamide, cytarabine
- Where
- Germany
- Sponsor
- Johann Wolfgang Goethe University Hospital
Lymphoma
Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002565
- Testing
- bleomycin sulfate, CHOP regimen, cisplatin
- Where
- 3 sites in United States, Brazil and 1 more
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003105
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B-Cell Lymphoma
R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis
Purpose: to evaluate an efficacy of chemotherapy regimens R-DA-EPOCH-21 and R-mNHL-BFM-90 with and without autologous hematopoietic stem cells transplantation (auto-SCT) in newly diagnosed patients with DLBCL with intermediate…
- Trial name
- NCT02842931
- Testing
- R-DA-EPOCH-21, R-DA-EPOCH-21 + auto-SCT, R-mNHL-BFM-90
- Where
- Russia
- Volunteers
- 300 people
- Sponsor
- National Research Center for Hematology, Russia
Non Hodgkin Lymphoma
Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy
A phase II prospective, non-randomized study. The study aim is to evaluate the feasibility and activity of high-dose therapy with stem cell in elderly patients with aggressive lymphoma relapsed FIT or resistant to first line…
- Trial name
- NCT02371161
- Testing
- R-DHAP/R-ICE
- Where
- 27 sites in Italy
- Volunteers
- 135 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Leukemia, Lymphoma
Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00040690
- Testing
- filgrastim, cyclophosphamide, cytarabine
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Medical Research Council
Germ Cell Tumors
Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis
Not randomized, multicentric, national phase II trial estimating the efficacy of an intensification protocol in patients with refractory germ cell tumors with relapse and bad prognosis.
- Trial name
- TICE (NCT00864318)
- Testing
- Paclitaxel, Ifosfamide, Carboplatine
- Where
- 12 sites in France
- Volunteers
- 101 people
- Sponsor
- Institut Claudius Regaud
Retroperitoneal Sarcoma, Liposarcoma
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS…
- Conditions
- Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
- Trial name
- STRASS2 (NCT04031677)
- Testing
- Surgery, Preoperative chemotherapy
- Where
- 176 sites in United States, Australia and 13 more
- Volunteers
- 250 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Rhabdomyosarcoma
Evolutionary Therapy for Rhabdomyosarcoma
This clinical trial will evaluate 4 different strategies of chemotherapy schedules in newly diagnosed participants with metastatic Fusion Positive (alveolar) Rhabdomyosarcoma.
- Trial name
- NCT04388839
- Testing
- Vincristine, Cyclophosphamide, Vinorelbine
- Where
- 18 sites in United States
- Volunteers
- 12 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Ewing Sarcoma, Myelosuppression
A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib
This study is a prospective, open label, randomized controlled clinical trial aimed at patients with Ewing's sarcoma who have not received systematic anti-tumor treatment in the past.
- Trial name
- NCT06699472
- Testing
- Chemotherapy, Trilaciclib Injection [Cosela]
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Fudan University
Extranodal NK-T-CELL LYMPHOMA
Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma
Assess responses, progression free survival (PFS) and overall survival (OS) of the combination of GIFOX-B chemotherapy with intensity-modulated radiation therapy (IMRT) in Stage IB or bulky disease - II and without IMRT in Stage…
- Trial name
- Gifox-B (NCT02808091)
- Testing
- GIFOX-Bortezomib, IMRT
- Where
- Singapore
- Volunteers
- 7 people
- Sponsor
- National Cancer Centre, Singapore
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00788125
- Testing
- carboplatin, dasatinib, etoposide phosphate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Neurofibromatosis Type 1, Sarcoma
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00304083
- Testing
- filgrastim, doxorubicin hydrochloride, etoposide
- Where
- 17 sites in United States
- Volunteers
- 48 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Mantle-Cell Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
The investigator(s) hypothesize that Rituximab together with combination chemotherapy, followed by Rituximab maintenance therapy, will provide better disease control with improved response rates and overall survival in patients…
- Trial name
- NCT00878254
- Testing
- G-CSF, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Miami
Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Malignant Germ Cell Tumor
Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
This phase II trial is studying how well giving combination chemotherapy works in treating young patients with recurrent or resistant malignant germ cell tumors.
- Conditions
- Childhood Extracranial Germ Cell Tumor, Childhood Extragonadal Malignant Germ Cell Tumor, Childhood Malignant Ovarian Germ Cell Tumor, Childhood Malignant Testicular Germ Cell Tumor
- Trial name
- NCT00467051
- Testing
- Carboplatin, Filgrastim, Ifosfamide
- Where
- 95 sites in United States, Australia and 2 more
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group